Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/-mice

AIM To investigate the synergistic hepato-protective properties of curcumin and vitamin E in an Hfe^(-/-)high calorie diet model of steatohepatitis.METHODS Hfe^(-/-)C57BL/6J mice were fed either a high calorie diet or a high calorie diet with 1 mg/g curcumin; 1.5 mg/g vitamin E; or combination of 1 mg/g curcumin + 1.5 mg/g vitamin E for 20 wk. Serum and liver tissue were collected at the completion of the experiment. Liver histology was graded by a pathologist for steatosis, inflammation and fibrosis. RNA and protein was extracted from liver tissue to examine gene and protein expression associated with fatty acid oxidation, mitochondrial biogenesis and oxidative stress pathways.RESULTS Hfe^(-/-)mice fed the high calorie diet developed steatohepatitis and pericentral fibrosis. Combination treatment with curcumin and vitamin E resulted in a greater reduction of percent steatosis than either vitamin E or curcumin therapy alone. Serum alanine aminotransferase and non-alcoholic fatty liver disease(NAFLD) activity score were decreased following combination therapy with curcumin and vitamin E compared with high calorie diet alone. No changes were observed in inflammatory or fibrosis markers following treatment. Epididymal fat pad weights were significantly reduced following combination therapy, however total body weight and liver weight were unchanged. Combination therapy increased the m RNA expression of Adipo R2, Ppar-α, Cpt1 a, Nrf-1 and Tfb2 m suggesting enhanced fatty acid oxidation and mitochondrial biogenesis. In addition, combination treatment resulted in increased catalase activity in Hfe^(-/-)mice. CONCLUSION Combination curcumin and vitamin E treatment decreases liver injury in this steatohepatitis model, indicating that combination therapy may be of value in NAFLD.

Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study

Objective:Depression is a global and growing health issue.Complementary and alternative medicines (CAM) use is common among people with depression.We examined the baseline use of CAM (products,not services) in centrally obese adults with depression,a specific and increasingly important population who were part of a trial of Tai Chi and Qigong for depression.Methods:Self-reported use of CAM products (four major groups:vitamins,herbal medicines,mineral supplements and purified chemicals as nutritional supplements) together with demographic,lifestyle and health status characteristics were collected using validated questions within a written survey.We used descriptive statistics to understand patterns of use.Results:Two hundred and sixty patients participated in the assessment.Half of the patients stated they were using CAM,on average reporting 2.3 CAM per patient.Women were more likely than men,and older people (>60 years) more likely than younger people (<40 years) to use any CAM products.Patients reported using CAM mostly for general health and alleviating aches and pains.CAM use was not associated with health state,use of a prescription antidepressant medicine,nor (self-reported) comorbidities such as arthritis,diabetes,hypertension or alcohol or tobacco use.Conclusions:CAM products are commonly used in Australians with moderate depression,particularly in female or older patients.The range and number of CAM in this group with common comorbidity may present additional unknown risks due to potential interactions with other prescribed medications with a myriad of biological and pharmacological effects.The importance of establishing whether depressed patients are taking CAM,the particular CAM and whether the CAM interacts with each other,other drugs used for depression or the biological process of the depression itself are factors to be considered at each assessment.

Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease(NAFLD)presents a chronic condition that links the overarching influence of the intestinal microbiome to a disease state with the multisystem manifestations of obesity,type 2 diabetes(T2D),chronic kidney disease(CKD)and cardiovascular disease(CVD)(1).NAFLD is an increasingly common disease with a current prevalence of 25%worldwide(2).The proportion of severe presentations of NAFLD is also increasing and these trends will lead to an increased burden from NAFLD sequelae,including cirrhosis,liver failure and hepatocellular cancer(2).